
Shares of Amicus Therapeutics FOLD.O rise 30% to $14.16 premarket
BioMarin Pharmaceutical BMRN.O to buy FOLD in an all-cash deal worth about $4.8 billion
BMRN will pay $14.50 per share for FOLD, a premium of 33.1% to the stock's last close
BMRN gains access to FOLD's treatments for genetic disorders Fabry disease and Pompe disease
Up to last close, FOLD shares up 15.6% YTD